19 reports

Abstract: - Global Statin Market to Reach $16.3 Billion by 2027 - Amid the COVID-19 crisis, the global market for Statin estimated at US$14.1 Billion in the year 2020, is projected to reach a revised size of US$16.3 Billion by 2027, growing at aCAGR of 2.1% over the period 2020-2027. Synthetic Statins, one of the segments...

  • Statins
  • World
  • China
  • United States

The global statin market is currently witnessing stable growth. Statin is a lipid-lowering medication, an agent that is consumed by patients to reduce their blood cholesterol levels. Atorvastatin, rosuvastatin, lovastatin and simvastatin are the most common types of statins available in the market. They aid in preventing...

  • Statins
  • World

About this market The increasing statin use will help the market grow at a steady rate. In the US and the UK, people aged 40 and above are recommended to monitor their cholesterol level. Statins are considered an evidence-based treatment for high risk patients with elevated cardiovascular disorder. Technavio’s analysts...

  • Statins
  • World
  • United States
  • United Kingdom
  • Number Of Enterprises
  • Cause-Specific Mortality Rate

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Statins
  • World

This study covers the world outlook for statins across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks...

  • Statins
  • World
  • Gross Domestic Product
  • Disposable Income

Coenzyme Q10 also known as ubiquinone, is a fat-soluble vitamin-like compound, which acts as a cofactor and is required by large and complex enzymes to carry out their functions.CoQ10 is available in three redox states: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol), of which ubiquinone is the most...

  • Dietary Supplement
  • Pharmaceutical
  • Cardiology
  • Statins
  • World
  • North America
  • Japan
  • APAC
  • Energy Supply

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Cardiovascular Disease
  • Packaging
  • Statins
  • World

United States World Statins

  • Pharmaceutical
  • Healthcare
  • Statins
  • World
  • Drug Approval
  • Pharmaceutical Registrations

Cardiovascular Disorders Drug Development Pipeline Review, 2017 Summary Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic...

  • Cholesterol
  • Pharmaceutical
  • Heart Failure
  • Hypertension
  • Antihypertensive
  • Statins

Statins

  • Cardiovascular Disease
  • Therapy
  • Statins
  • Chronic Disease
  • Clinical Trial
  • World
  • Drug Approval
  • Chronic Disease Prevalence

##.## Statins: HMG-CoA Reductase Inhibitors

  • Hospital
  • Therapy
  • Statins
  • Cardiovascular Drug
  • Acute Coronary Syndrome
  • ACE Inhibitor
  • World
  • Hospital Occupancy Rate
  • Infectious Disease Mortality

Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology? PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have relegated them to third-line use. Can they move up the treatment...

  • Lipid Modifying Drug
  • Antisense Technology
  • Statins
  • Clinical Trial
  • United States
  • North America
  • World
  • Europe
  • Utah

Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The dyslipidemia drugs market promises lucrative...

  • Cholesterol
  • Statins
  • World
  • APAC
  • Europe
  • North America
  • Latin America
  • Africa

The question of whether to approve Regeneron and Sanofi’s Praluent (alirocumab) and Amgen’s Repatha (evolocumab) never really seemed to be in doubt at FDA’s Endocrinologic and Metabolic Drugs Advisory Committee meetings on Tuesday and Wednesday, as panel members by and large expressed...

  • Health Care Provider
  • Statins
  • European Union

Amgen and Sanofi/Regeneron Pharmaceuticals may be locked in one of the most intriguing US drug regulatory races of recent memory, but it is the European Medicines Agency that has provided a first definitive regulatory action for the PCSK9 inhibitor class by recommending approval of Amgen's...

  • Statins
  • Health Care Provider
  • Europe
  • United States

Biotech is a notoriously volatile sector, and pure-play nonalcoholic steatohepatitis (NASH) drug developers have for the past couple years occupied one of the more volatile neighbourhoods within it thanks to growing appreciation for the how big the multi-billion dollar market could be and,...

  • Cholesterol
  • Cardiology
  • Digestive System Disorder
  • Hormone
  • Autoimmune Disease
  • Statins

Last week saw Esperion Therapeutics release promising Phase IIb data for its oral hypercholesterolaemia treatment ETC-1002. When added to stable statin therapy, a 180mg dose of ETC-1002 demonstrated a 24 percent incremental reduction in LDL-cholesterol versus those patients treated only with...

  • Statins
  • United States

Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight the potential cost of treatment to the US healthcare system associated with a new class of dyslipidaemia therapies called PCSK9 inhibitors. The two most advanced drugs in this class – Sanofi and Regeneron...

  • Health Care Provider
  • Statins
  • United States
  • Drug Approval

As many have speculated, final data from Merck & Co.'s long-awaited IMPROVE-IT study has implications that stretch far beyond the commercial performance of the drug assessed in the trial; ezetimide (sold by Merck as Zetia or Vytorin when combined with simvastatin). Nine...

  • Cardiology
  • Cholesterol
  • Statins
  • United States
  • Drug Approval